Jeffrey Matous, MD
Hematology & Oncology · Denver, CONPI 1992789036
Payments from drug & device makers
Across 1,100 payments — averaging $7644.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$4.6M
- Beigene, Ltd.$1.8M
- Bristol Myers Squibb$1.3M
- E.r. Squibb & Sons, L.L.C.$226K
- Genentech, Inc.$183K
- Takeda Pharmaceuticals U.S.A., Inc.$142K
- plus $161K from 24 others
Across 46 payments — averaging $3635.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$160K
- Beigene, Ltd.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Bristol Myers Squibb$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 638 | $4,568,222 |
| Beigene, Ltd. | 155 | $1,786,211 |
| Bristol Myers Squibb | 71 | $1,343,326 |
| E.r. Squibb & Sons, L.L.C. | 10 | $226,090 |
| Genentech, Inc. | 21 | $183,035 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $141,635 |
| Pharmacyclics LLC, An Abbvie Company | 47 | $53,408 |
| EMD Serono, Inc. | 3 | $48,771 |
| Beone Medicines Ltd. | 10 | $18,372 |
| Beigene USA, Inc. | 15 | $17,284 |
| Johnson & Johnson | 21 | $9,690 |
| Seagen Inc. | 7 | $5,885 |
| Beigene Switzerland GmbH | 3 | $3,405 |
| AbbVie | 15 | $2,210 |
| Pfizer | 1 | $630 |
| Sanofi | 4 | $352 |
| Beone Medicines USA, Inc. | 2 | $280 |
| Amgen | 2 | $139 |
| Gilead(2 entities) | 2 | $97 |
| Genentech USA, Inc. | 3 | $63 |
| Blueprint Medicines Corporation | 2 | $52 |
| Geron Corporation | 1 | $38 |
| Merck | 2 | $36 |
| Agios Pharmaceuticals, Inc. | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Legend Biotech USA Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Terumo BCT, Inc. | 1 | $16 |
| Novartis | 1 | $12 |
How this compares
$8,409,368 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Denver
- Allen CohnDenver$13.5M
- Robert RifkinDenver$11.3M
- Henning SchadeDenver$9M
- Peter ForsbergDenver$5.5M
- Tara GregoryDenver$3.5M
- Mabel MardonesDenver$3M
- Amy SchmidtDenver$2.8M
- Michael TeesDenver$2.7M
- Yousuf GaffarDenver$1.8M
- Michael MarisDenver$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.